Welcome to the UPF Digital Repository

Gal-1 expression analysis in the GLIOCAT multicenter study: Role as a prognostic factor and an immune-suppressive biomarker

Show simple item record

dc.contributor.author Martínez Bosch, Neus
dc.contributor.author Alameda Quitllet, Francisco
dc.contributor.author Arumí Uría, Montserrat
dc.contributor.author Bellosillo Paricio, Beatriz
dc.contributor.author Menéndez, Silvia
dc.contributor.author Esteve-Codina, Anna
dc.contributor.author Martínez-García, Maria
dc.contributor.author Navarro Medrano, Pilar
dc.date.accessioned 2023-06-15T06:00:25Z
dc.date.available 2023-06-15T06:00:25Z
dc.date.issued 2023
dc.identifier.citation Martínez-Bosch N, Vilariño N, Alameda F, Mojal S, Arumí-Uria M, Carrato C, et al. Gal-1 expression analysis in the GLIOCAT multicenter study: Role as a prognostic factor and an immune-suppressive biomarker. Cells. 2023 Mar 8;12(6):843. DOI: 10.3390/cells12060843
dc.identifier.issn 2073-4409
dc.identifier.uri http://hdl.handle.net/10230/57171
dc.description.abstract Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof Cells. 2023 Mar 8;12(6):843
dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Gal-1 expression analysis in the GLIOCAT multicenter study: Role as a prognostic factor and an immune-suppressive biomarker
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/cells12060843
dc.subject.keyword Galectin-1
dc.subject.keyword IDH-1
dc.subject.keyword Glioblastoma
dc.subject.keyword Immune-suppression
dc.subject.keyword Mesenchymal molecular subtype
dc.subject.keyword Prognostic factor
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking